Memorial Sloan Kettering Cancer Center @MSKCancerCenter · 26 Aug 2026
The @FDA has approved #daraxonrasib for certain patients with metastatic pancreatic cancer. MSK’s @EileenMOReilly led the phase 3 trial at MSK showing it doubled median survival compared with chemotherapy. “To date in my career, I have not seen this level of benefit from any https://t.co/JJnRtO7O14
25 223Views
217Likes
58Reposts
5Replies
8Quotes
20Bookmarks
Is that a lot?
11.2×vs this author's median2 254 views is typical
83Percentile for this authorof 6 recent posts
4.08×vs 100K–1M median6 178 views is typical
24.26%Reachviews ÷ followers
1.14%Engagement rateof viewers reacted